Evidence map›Paper›PMID 33468703›Full record

ArticlemBio2021

Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses

Nathan E Stone, Sierra A Jaramillo, Ashley N Jones, Adam J Vazquez, Madison Martz, Lora M Versluis, Marlee O Raniere, Haley E Nunnally, Katherine E Zarn, Roxanne Nottingham and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. SARS-CoV-2 and the DNA damage response.The Journal of general virology · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. NADTrends in immunology · 2022
    Review
  14. Article
  15. Article
  16. Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Nathan E StonePathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Sierra A JaramilloPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Ashley N JonesPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Adam J VazquezPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Madison MartzPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Lora M VersluisPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Marlee O RanierePathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Haley E NunnallyPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Katherine E ZarnPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Roxanne NottinghamPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Ken R NgPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Jason W SahlPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
David M WagnerPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID 0000-0003-2684-6007
Steen KnudsenAllarity Therapeutics, Hørsholm, Denmark.
Erik W SettlesPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Paul KeimPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID 0000-0003-0089-5820
Christopher T FrenchPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA ctfrench@nau.edu.
Northern Arizona University · USMC2 Therapeutics (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By late 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused tens of millions of infections and over 1 million deaths worldwide. A protective vaccine and more effective therapeutics are urgently needed. We evaluated a new poly(ADP-ribose) polymerase (PARP) inhibitor, stenoparib, that recently advanced to phase II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronaviruses, including SARS-CoV-2,

Indexed as

Adenosine MonophosphateAlanineAnimalsAntimetabolitesAntiviral AgentsAzo CompoundsChlorocebus aethiopsCoronavirus NL63, HumanCOVID-19COVID-19 Drug TreatmentDrug RepositioningHumansIsoquinolinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesQuinazolinonesAdenosine MonophosphateAlanineAntimetabolitesAntiviral AgentsAzo CompoundsIsoquinolinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesQuinazolinonesremdesivirstenoparibCOVID-19NL63PARPSARS-CoV-2stenoparib

Identifiers

PMID33468703
PMCPMC7845641
OpenAlexW3121160585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.